Topic resource collection
Approved comparison material connected to this topic.
5 resourcesRead both sides
BPC-157 VEGF/FGF-2 upregulation → angiogenesis and fibroblast migration to injury zone 250–500 mcg daily SC for 8–12 weeks Animal tendon models only; no human RCTs for labral tears Begin week 2–3 post-injury; pair with progressiv…
Conservative (PT + NSAIDs) Symptom management, no tissue repair 6–12 weeks (if effective) None. Relies on existing blood supply High (55% remain symptomatic) Does not address avascularity; effective only for minor peripheral tear…
BPC-157 VEGF upregulation, angiogenesis, fibroblast proliferation 250–500 mcg/day Inflammatory + Early Proliferative (Days 1–14) Once or twice daily subcutaneous First-line peptide for acute soft tissue injuries. Strongest eviden…
| Peptide | Primary Mechanism | Target Tissue | Inflammation Effect | Typical Dosing (Research Models) | Storage Sensitivity | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | Upregulates VEGF and fibroblast growth factor; promo…
Each peptide targets different aspects of the inflammatory and repair cascade. Here's how they compare in practical application. BPC-157 VEGF pathway activation, angiogenesis promotion in hypoxic tissue 250–500 mcg/day Once or tw…